Latest research on Salbutamol

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Salbutamol indications

In the first study evaluating the combination of a beta agonist and ICS (Salbutamol, 1200 μg/kg/d and beclomethasone, 1000 μg/kg/d), the effectiveness of treatment was assessed using long-term outcomes such as BPD and death, and no significant differences were found between treatment groups and placebo [36]. [source, 2016]
Fok et al. [18] and Kao et al. [37] revealed through measurements of Rrs that the bronchodilator effect of Salbutamol subsides after two and three hours respectively. [source, 2016]
Brundage et al. demonstrated that the synergistic effect of combined Salbutamol and Ipratropium Bromide can promote a longer bronchodilator effect than each drug given independently [46]. [source, 2016]
However, in a recent randomized placebo-controlled trial, the effects of the β2-adrenergic receptor agonist, Albuterol, in acute lung injury did not increase ventilator-free days or reduce the rate of death before hospital discharge [19]. [source, 2016]
Inhaled Salbutamol has also been shown to be effective in treating attacks of Hyper PP. [source, 2016]
In the present study we investigated the effects of Salbutamol on MKP-1 expression and further, whether MKP-1 is involved in the anti-inflammatory effects of this β2-receptor agonist. [source, 2016]
Next, we investigated the effects of Salbutamol on MKP-1 expression in these cells. [source, 2016]
Therefore, we investigated the effect of β2-receptor agonists Salbutamol and terbutaline on p38 MAPK phosphorylation. [source, 2016]
As Salbutamol increased MKP-1 expression, we wanted to investigate whether MKP-1 could mediate the anti-inflammatory effects of Salbutamol, therefore we tested the effect of Salbutamol on the severity of carrageenan-induced paw inflammation in wild-type and MKP-1(-/-) mice. [source, 2016]
Carrageenan-induced paw edema was clearly attenuated by Salbutamol in wild-type mice (73% reduction in AUC value), while Salbutamol was less effective to reduce paw edema in MKP-1(-/-) mice (43% reduction in AUC value, p = 0,0148) (Fig 5). [source, 2016]